Literature DB >> 20333321

Anti-Inflammatory Agents for Cancer Therapy.

Elizabeth R Rayburn1, Scharri J Ezell, Ruiwen Zhang.   

Abstract

Inflammation is closely linked to cancer, and many anti-cancer agents are also used to treat inflammatory diseases, such as rheumatoid arthritis. Moreover, chronic inflammation increases the risk for various cancers, indicating that eliminating inflammation may represent a valid strategy for cancer prevention and therapy. This article explores the relationship between inflammation and cancer with an emphasis on epidemiological evidence, summarizes the current use of anti-inflammatory agents for cancer prevention and therapy, and describes the mechanisms underlying the anti-cancer effects of anti-inflammatory agents. Since monotherapy is generally insufficient for treating cancer, the combined use of anti-inflammatory agents and conventional cancer therapy is also a focal point in discussion. In addition, we also briefly describe future directions that should be explored for anti-cancer anti-inflammatory agents.

Entities:  

Year:  2009        PMID: 20333321      PMCID: PMC2843097          DOI: 10.4255/mcpharmacol.09.05

Source DB:  PubMed          Journal:  Mol Cell Pharmacol        ISSN: 1938-1247


  120 in total

Review 1.  Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?

Authors:  Sharlene Gill; Frank A Sinicrope
Journal:  Semin Oncol       Date:  2005-02       Impact factor: 4.929

2.  Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.

Authors:  G A Kune; S Kune; L F Watson
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

3.  Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial.

Authors:  R Calaluce; D L Earnest; D Heddens; J G Einspahr; D Roe; C L Bogert; J R Marshall; D S Alberts
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-12       Impact factor: 4.254

Review 4.  Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.

Authors:  Mark T Fleming; Michael J Morris; Glenn Heller; Howard I Scher
Journal:  Nat Clin Pract Oncol       Date:  2006-12

Review 5.  Therapy insight: Potential of statins for cancer chemoprevention and therapy.

Authors:  Matthew S Katz
Journal:  Nat Clin Pract Oncol       Date:  2005-02

6.  Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft.

Authors:  P E Kristjansen; Y Boucher; R K Jain
Journal:  Cancer Res       Date:  1993-10-15       Impact factor: 12.701

7.  Sulindac for polyposis of the colon.

Authors:  W R Waddell; R W Loughry
Journal:  J Surg Oncol       Date:  1983-09       Impact factor: 3.454

Review 8.  Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.

Authors:  Hang Xiao; Chung S Yang
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

9.  NO-donors (VII [1]): synthesis and cyclooxygenase inhibitory properties of N-and S-nitrooxypivaloyl-cysteine derivatives of naproxen -- a novel type of NO-NSAID.

Authors:  Rahmana E Kartasasmita; Stefan Laufer; Jochen Lehmann
Journal:  Arch Pharm (Weinheim)       Date:  2002-08       Impact factor: 3.751

10.  Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.

Authors:  Edward W Howard; Davy T Lee; Yung Tuen Chiu; Chee Wai Chua; Xianghong Wang; Yong Chuan Wong
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

View more
  90 in total

Review 1.  Microbial pigments as natural color sources: current trends and future perspectives.

Authors:  Hardeep S Tuli; Prachi Chaudhary; Vikas Beniwal; Anil K Sharma
Journal:  J Food Sci Technol       Date:  2014-10-10       Impact factor: 2.701

2.  Next generation sequencing and functional pathway analysis to understand the mechanism of action of copper-tolfenamic acid against pancreatic cancer cells.

Authors:  Myrna Hurtado; Laszlo Prokai; Umesh T Sankpal; Blair Levesque; Rajasekhar Maram; Jaya Chhabra; Deondra T Brown; Raj K Gurung; Alvin A Holder; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Process Biochem       Date:  2019-10-30       Impact factor: 3.757

3.  Deacetylation by SIRT1 Reprograms Inflammation and Cancer.

Authors:  Tie Fu Liu; Charles E McCall
Journal:  Genes Cancer       Date:  2013-03

4.  Novel Survivin Inhibitor for Suppressing Pancreatic Cancer Cells Growth via Downregulating Sp1 and Sp3 Transcription Factors.

Authors:  Myrna Hurtado; Umesh T Sankpal; Aboubacar Kaba; Shahela Mahammad; Jaya Chhabra; Deondra T Brown; Raj K Gurung; Alvin A Holder; Jamboor K Vishwanatha; Riyaz Basha
Journal:  Cell Physiol Biochem       Date:  2018-11-30

Review 5.  ITCH as a potential therapeutic target in human cancers.

Authors:  Qing Yin; Clayton J Wyatt; Tao Han; Keiran S M Smalley; Lixin Wan
Journal:  Semin Cancer Biol       Date:  2020-03-10       Impact factor: 15.707

6.  Synthesis and biological evaluation of RGD conjugated with Ketoprofen/Naproxen and radiolabeled with [99mTc] via N4(GGAG) for αVβ3 integrin-targeted drug delivery.

Authors:  Reza Mohammadi; Bahareh Shokri; Danial Shamshirian; Afshin Zarghi; Soraya Shahhosseini
Journal:  Daru       Date:  2019-12-16       Impact factor: 3.117

Review 7.  Mechanisms of Phytonutrient Modulation of Cyclooxygenase-2 (COX-2) and Inflammation Related to Cancer.

Authors:  Shreena J Desai; Ben Prickril; Avraham Rasooly
Journal:  Nutr Cancer       Date:  2018-03-26       Impact factor: 2.900

Review 8.  Synthetic high-density lipoprotein-like nanoparticles for cancer therapy.

Authors:  Linda Foit; Francis J Giles; Leo I Gordon; Colby Shad Thaxton
Journal:  Expert Rev Anticancer Ther       Date:  2014-12-09       Impact factor: 4.512

Review 9.  Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype.

Authors:  Abigail C Cornwell; Michael E Feigin
Journal:  Trends Pharmacol Sci       Date:  2020-10-22       Impact factor: 14.819

10.  5-((1-Aroyl-1H-indol-3-yl)methylene)-2-thioxodihydropyrimidine-4,6(1H,5H)-diones as potential anticancer agents with anti-inflammatory properties.

Authors:  Narsimha Reddy Penthala; Purushothama Rao Ponugoti; Vinod Kasam; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2012-12-22       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.